This list of U.S.-based National Institutes of Health trials is derived from the NIH's database and includes phase I-III overactive bladder trials and phase IV BPH trials that are currently recruiting participants. This list is current as of April 19, 2012. For more information, view the complete database at http://ClinicalTrials.gov.
Overactive Bladder
■ Combined Behavioral and Drug Treatment of Overactive Bladder in MenSponsor(s): University of Alabama at Birmingham
Identifier: NCT01175382
■ A Study of the Pharmacokinetics and Pharmacodynamics of MK4618 in Women With OAB (MK-4618-004)Sponsor(s): Merck
Identifier: NCT01500382
■ Botox for the Treatment of OAB Secondary to Benign Prostatic ObstructionSponsor(s): Weill Medical College of Cornell University
Identifier: NCT01220726
■ Refractory OAB: Sacral NEuromodulation v. BoTulinum Toxin Assessment (ROSETTA)Sponsor/Collaborators: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Duke University; University of Alabama at Birmingham; University of California, San Diego; The Cleveland Clinic; Brown University; University of New Mexico; University of Pennsylvania; University of Pittsburgh; Oregon Health and Science University; RTI International
Identifier: NCT01502956
■ Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic OABSponsor(s): Allergan
Identifier: NCT00439140
■ Safety and Efficacy Study of AGN-214868 in Patients With Idiopathic OAB and Urinary IncontinenceSponsor(s): Allergan
Identifier: NCT01157377
BPH
■ PROLIEVE Post-Marketing Study Treatment of BPHSponsor(s): Boston Scientific Corporation
Identifier: NCT00407953
■ Phase 4 Study of Greenlight XPS Laser Versus BiVAP Saline Vaporization of the Prostate in Men With Symptomatic BPHSponsor/Collaborators: Brooklyn Urology Research Group; American Medical Systems; Richard Wolf Medical Instruments Corporation
Identifier: NCT01500057
■ An Open Label Study to Measure Efficacy of Fesoterodine (Toviaz) Post Surgery for BPHSponsor/Collaborators: Weill Medical College of Cornell University; Pfizer
Identifier: NCT00605319
From evidence to practice: Dr. Makarov discusses implementation science in urology
July 25th 2024“What our major contribution is, I think as urologists doing implementation science, is determining the important questions, which we are particularly well-suited to do because we're taking care of the patients,” says Danil V. Makarov, MD, MHS.
Phase 1B trial to evaluate relugolix and enzalutamide in high-risk prostate cancer
July 24th 2024"Going forward after this study, we hope to be able to expand and potentially look at patients undergoing either surgery or radiation therapy, and really try to determine the potential benefit," says Kelly L. Stratton, MD, FACS.